Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women

Powers, Douglas C.

doi:10.1128/cdli.1.1.16-20.1994

Cited by 9 publications

(1 citation statement)

References 18 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 60 eligible articles published between 1987 and 2006 describing inactivated seasonal influenza vaccine immunogenicity studies conducted in the United States, Canada, Europe, Israel, and Russia 10,22–80 . We included 129 independent study arms of which 119 reported data on response to A/H1N1, 109 on influenza B, and 108 on A/H3N2 vaccine strains (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Quantitative review of antibody response to inactivated seasonal influenza vaccines

Seidman

Richard

Viboud

et al. 2011

Influenza Resp Viruses

View full text Add to dashboard Cite

Please cite this paper as: Seidman et al. (2012) Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza and Other Respiratory Viruses 6(1), 52–62. Background Seasonal influenza epidemics are associated with significant morbidity and mortality each year, particularly amongst young children and the elderly. Seasonal influenza vaccines have been available for decades, yet influenza remains a major public health threat in the US, sparking interest in studies evaluating the effectiveness of vaccination. Objectives We sought to identify determinants of serological responses to inactivated seasonal influenza vaccines including number of doses, adjuvant, and subject characteristics. Methods We reviewed 60 articles published between 1987 and 2006. We used weighted multiple logistic regression and random‐effects models to evaluate how seroconversion and seroprotection rates varied with host and vaccine factors. Results Both children and seniors tended to have poorer immune responses compared to adults whereas use of adjuvant and a second vaccine dose tended to improve immune response. Pre‐vaccination serological status had a large impact on the immune response to vaccination. We found substantial heterogeneity among studies, even with similar population settings and vaccination regimen. Conclusions Future studies should stratify their results by pre‐vaccination serological status in an effort to produce more precise summary estimates of vaccine response.

show abstract

Section: Resultsmentioning

confidence: 99%

Quantitative review of antibody response to inactivated seasonal influenza vaccines

Seidman

Richard

Viboud

et al. 2011

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

The cell-mediated cytotoxic response to influenza vaccination using an assay for granzyme B activity

McElhaney¹,

Pinkoski²,

Upshaw³

et al. 1996

Journal of Immunological Methods

View full text Add to dashboard Cite

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

Mbawuike¹,

Zang²,

Couch³

2007

Vaccine

View full text Add to dashboard Cite

To evaluate humoral (antibody) and cell mediated immune (CMI) responses, 30 healthy young adults were either given inactivated influenza vaccine with or without QS21 adjuvant. Vaccination site pain and postvaccination myalgias were greater in the QS21 group. Serum antibody increases occurred in 73 to 93% of subjects for each vaccine and antigen at 2 weeks and 4 weeks but frequencies and mean titers for the two vaccines were not different. No differences in T cell cytotoxicity were detected for either vaccine for influenza A or B infected cells. IFN-γ for both vaccine groups was increased in supernates after 3 days but not 7 days of stimulation in the cytotoxicity tests; amounts for the two vaccines were similar. To further evaluate CMI, remaining PBMCs were stimulated overnight with cells infected with each vaccine strain; an increase in spot forming cells (sfc) for Granzyme B and IFN-γ was found for all subjects and in 51 of 54 sfc tests. A slightly higher response in the Gran B test for QS21 subjects was suggested, but no clear immune response advantage was identified among healthy adults for QS21 adjuvanted influenza vaccine.

show abstract

Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women

Cited by 9 publications

References 18 publications

Quantitative review of antibody response to inactivated seasonal influenza vaccines

Quantitative review of antibody response to inactivated seasonal influenza vaccines

The cell-mediated cytotoxic response to influenza vaccination using an assay for granzyme B activity

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

Contact Info

Product

Resources

About